Computationally Designed Stapled Peptides as Theranostics Targeting S100B in Cancer and Neurodegeneration
Structure-guided computational design produced optimized stapled macrocyclic peptides that bind S100B(ββ) with high predicted affinity and can serve dual roles as both diagnostic imaging agents and therapeutic inhibitors.
Quick Facts
What This Study Found
Computationally designed stapled macrocyclic peptides predicted to bind S100B(ββ) with high affinity. Modified with imaging agents for theranostic applications. Designed to disrupt S100B-partner protein interactions driving cancer and neurodegeneration.
Key Numbers
Multiple optimized stapled peptide analogs with predicted high-affinity S100B binding
How They Did This
Computational study. Comparative structural analysis of S100B-peptide complexes. Molecular dynamics simulations. Stapled peptide design and in silico mutagenesis optimization. Imaging agent conjugation for theranostic functionality.
Why This Research Matters
S100B is implicated in melanoma, glioblastoma, Alzheimer's, and inflammatory conditions but has been "undruggable" with small molecules. Stapled peptides that both diagnose and treat could transform S100B-driven disease management.
The Bigger Picture
Theranostic peptides — combining diagnosis and treatment in one molecule — represent a growing trend in precision medicine. Targeting S100B with such agents could enable personalized treatment decisions based on real-time biomarker monitoring.
What This Study Doesn't Tell Us
Entirely computational — no experimental binding validation. Predicted affinities require in vitro confirmation. In vivo peptide delivery and imaging agent function not tested. Stapled peptide cell permeability assumed but not verified.
Questions This Raises
- ?Do the designed stapled peptides actually bind S100B with the predicted affinity?
- ?Can the imaging agent-conjugated peptides detect S100B levels in vivo?
- ?Would S100B inhibition slow cancer or neurodegeneration progression?
Trust & Context
- Key Stat:
- Theranostic peptides Same peptide molecule can both detect S100B levels (diagnosis) and block S100B disease-driving interactions (treatment) — precision medicine in one agent
- Evidence Grade:
- Low evidence grade: computational design study with no experimental validation. Predictions require in vitro and in vivo confirmation.
- Study Age:
- Published 2021. S100B as a therapeutic target continues to be explored with both peptide and small molecule approaches.
- Original Title:
- Computational Design of Macrocyclic Binders of S100B(ββ): Novel Peptide Theranostics.
- Published In:
- Molecules (Basel, Switzerland), 26(3) (2021)
- Authors:
- Kannan, Srinivasaraghavan(3), Aronica, Pietro G A(2), Nguyen, Thanh Binh, Li, Jianguo, Verma, Chandra S
- Database ID:
- RPEP-05480
Evidence Hierarchy
Frequently Asked Questions
What is S100B and why does it matter?
S100B is a protein that, when present at high levels, is linked to melanoma, brain cancer, Alzheimer's disease, and brain injury. It's already used as a blood biomarker for brain damage. Drugs that block it could potentially treat these conditions.
What is a theranostic?
A theranostic is a single agent that combines diagnosis and treatment. These designed peptides can both detect S100B (using attached imaging agents) and block its harmful interactions (through high-affinity binding) — enabling doctors to diagnose and treat simultaneously.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05480APA
Kannan, Srinivasaraghavan; Aronica, Pietro G A; Nguyen, Thanh Binh; Li, Jianguo; Verma, Chandra S. (2021). Computational Design of Macrocyclic Binders of S100B(ββ): Novel Peptide Theranostics.. Molecules (Basel, Switzerland), 26(3). https://doi.org/10.3390/molecules26030721
MLA
Kannan, Srinivasaraghavan, et al. "Computational Design of Macrocyclic Binders of S100B(ββ): Novel Peptide Theranostics.." Molecules (Basel, 2021. https://doi.org/10.3390/molecules26030721
RethinkPeptides
RethinkPeptides Research Database. "Computational Design of Macrocyclic Binders of S100B(ββ): No..." RPEP-05480. Retrieved from https://rethinkpeptides.com/research/kannan-2021-computational-design-of-macrocyclic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.